Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2A Trial to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of SQ109 in Adult Subjects With Newly Diagnosed, Uncomplicated, Smear-Positive, Pulmonary Tuberculosis

NCT01218217 is registered in ClinicalTrials.gov with Michael Hoelscher as lead sponsor.

NCT NCT01218217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01218217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2A Trial to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of SQ109 in Adult Subjects With Newly Diagnosed, Uncomplicated, Smear-Positive, Pulmonary Tuberculosis
Lead sponsor
Michael Hoelscher
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2010
Completion date
May 31, 2012
Enrollment
90 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis, pulmonary